Evaluation of a radical Prostatectomy Treated Patient Cohort in the Military Health System Identifies p53 Expression and Lymphovascular Invasion as Eearly Predictors of Metastatic Progression

William Gesztes1,2, Cara Schafer1,2, Denise Young1,2, Jesse Fox1,2, Yongmei Chen1,2, Huai-Ching Kuo1,2, Kuwong B. Mwamukonda4, Albert Dobi1,2, Gyorgy Petrovics1,2, Allen Burke3, Judd W. Moul1,4, David G. McLeod1,4÷, Inger L. Rosner1,4, Shyh-Han Tan1,2, Jennifer Cullen1,2, Shiv Srivastava1,5, Isabell A. Sesterhenn3 1Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA; 2Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, 20817 USA; 3Joint Pathology Center; Silver Spring, Maryland 20906, USA; 4Urology Service, Walter Reed National Military Medical Center, Bethesda, Maryland 20852, USA Background Summary & Conclusions Methods Results Prostate cancer incidence is the highest and is the second deadliest of cancers among American men. Although availability of several tests based on the detection of PSA, kallikrein proteins, or mRNA has improved the management of localized prostate cancer, the is an urgent need to identify early molecular biomarkers that would predict disease progression following treatment. Given the high representation of men in the US military, identification of early molecular biomarkers within a military cohort supports mission readiness and return to duty across all uniformed services. TP53 is one of the most frequently altered genes in primary prostate cancer. The precise assessment of its focal alterations in localized primary tumors by using immunohistochemistry (IHC) assay has significantly aided the prognosis of prostate cancer. Here, we evaluated the p53 protein expression as a surrogate for the detection of TP53 mutations and prostate lymphatic vessel invasion (LVI) for predicting metastatic progression. • p53 expression of >5% strongly correlates with positive LVI status. • Multivariate analysis suggests p53 expression and LVI status confers additive risk for DM. • Tumo
RITM0027793
Prostate cancer incidence is the highest and is the second deadliest of cancers among American men. Although availability of several tests based on the detection of PSA, kallikrein proteins, or mRNA has improved the management of localized prostate cancer, the is an urgent need to identify early molecular biomarkers that would predict disease progression following treatment. Given the high representation of men in the US military, identification of early molecular biomarkers within a military cohort supports mission readiness and return to duty across all uniformed services. TP53 is one of the most frequently altered genes in primary prostate cancer. The precise assessment of its focal alterations in localized primary tumors by using immunohistochemistry (IHC) assay has significantly aided the prognosis of prostate cancer. Here, we evaluated the p53 protein expression as a surrogate for the detection of TP53 mutations and prostate lymphatic vessel invasion (LVI) for predicting metastatic progression.